GlassScriptPhysician profile
Mustafa Huseini
NPI 1073613808
$5,368.53
in general payments reported to CMS, 2019-2025
21 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2021: $758 · 2022: $1,640 · 2023: $2,358 · 2024: $246 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,866 · Food and Beverage: $933 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,866.27 |
| Food and Beverage | $932.56 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $3,180.90 | 2021-2023 | Disposable Distal Attachment, Olympus, Single Use Electrosurgical Hemostatic Forceps |
| Apollo Endosurgery US INC | $1,148.83 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $217.30 | 2022-2025 | |
| Gilead Sciences, INC. | $117.57 | 2022-2025 | |
| Intuitive Surgical, INC. | $107.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $72.35 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $63.20 | 2024-2025 | Eohilia, Entyvio |
| Olympus America INC. | $62.22 | 2023 | Endoclot Phs, Disposable Emr Kit, Endoclot Sis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.53 | 2022-2025 | Xifaxan |
| Erbe USA INC | $50.00 | 2019 | |
| Endogastric Solutions, INC | $46.28 | 2022-2023 | Esophyx |
| Boston Scientific Corporation | $45.91 | 2024-2025 | Apollo Esg Nxt System, X-Tack Endoscopic Helix Tacking System |
| Madrigal Pharmaceuticals | $37.18 | 2024 | Resmetirom |
| Celgene Corporation | $32.33 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $23.28 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $20.55 | 2024 | Sucraid |
| Janssen Biotech, INC. | $19.14 | 2024 | Simponi, Stelara, Tremfya |
| Phadia US INC. | $16.82 | 2022 | |
| Ardelyx, INC. | $16.27 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $15.94 | 2022 | |
| Genzyme Corporation | $15.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Huseini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.